Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist known to delay gastric emptying. Despite a growing body of evidence, its peri-operative safety profile remains uncertain, particularly with regard to the risk of increased residual gastric content and aspiration of gastric contents during anaesthesia. We hypothesised that semaglutide interruption of ≤ 10 days before elective surgical procedures is insufficient to reduce or normalise the residual gastric content, despite fasting intervals that comply with current guidelines.

中文翻译：

---

通过胃超声评估残余胃内容物与围手术期 semaglutide 使用之间的关系：一项前瞻性观察研究


Semaglutide 是一种长效胰高血糖素样肽-1 受体激动剂，已知可延迟胃排空。尽管证据越来越多，但其围手术期安全性仍不确定，特别是关于麻醉期间残余胃内容物增加和胃内容物误吸的风险。我们假设在择期手术前 10 天停用 semaglutide ≤ 不足以减少或使残余胃内容物正常化，尽管禁食间隔符合当前指南。